NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$20.68 -0.36 (-1.71 %)
(As of 07/16/2018 02:37 PM ET)
Previous Close$20.88
Today's Range$20.60 - $21.06
52-Week Range$12.89 - $20.75
Volume35,107 shs
Average Volume1.21 million shs
Market Capitalization$3.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.99
Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Receive IRWD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IRWD
CUSIP46333X10
Phone617-621-7722

Debt

Debt-to-Equity Ratio-21.52
Current Ratio4.42
Quick Ratio4.40

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$298.28 million
Price / Sales10.53
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book295.43

Profitability

EPS (Most Recent Fiscal Year)($0.93)
Net Income$-116,930,000.00
Net Margins-34.12%
Return on Equity-2,073.20%
Return on Assets-20.90%

Miscellaneous

Employees730
Outstanding Shares151,940,000
Market Cap$3,196.84

The Truth About Cryptocurrencies

Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions

What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to analysts' expectations of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The business's quarterly revenue was up 32.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) earnings per share. View Ironwood Pharmaceuticals' Earnings History.

When is Ironwood Pharmaceuticals' next earnings date?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

What price target have analysts set for IRWD?

9 brokerages have issued twelve-month price targets for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $19.4444 in the next year. This suggests that the stock has a possible downside of 6.0%. View Analyst Ratings for Ironwood Pharmaceuticals.

What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Who are some of Ironwood Pharmaceuticals' key competitors?

Who are Ironwood Pharmaceuticals' key executives?

Ironwood Pharmaceuticals' management team includes the folowing people:
  • Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 54)
  • Ms. Gina R. Consylman C.P.A., CFO, Sr. VP & Treasurer (Age 45)
  • Dr. Mark G. Currie, Sr. VP, Chief Scientific Officer and Pres of R&D (Age 63)
  • Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 48)
  • Mr. Thomas A. McCourt, Sr. VP of Marketing & Sales and Chief Commercial Officer (Age 61)

Has Ironwood Pharmaceuticals been receiving favorable news coverage?

Media stories about IRWD stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 0.05 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.85 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Ironwood Pharmaceuticals' major shareholders?

Ironwood Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%) and V Wealth Management LLC (0.01%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

Which major investors are selling Ironwood Pharmaceuticals stock?

IRWD stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Which major investors are buying Ironwood Pharmaceuticals stock?

IRWD stock was acquired by a variety of institutional investors in the last quarter, including V Wealth Management LLC. View Insider Buying and Selling for Ironwood Pharmaceuticals.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ironwood Pharmaceuticals' stock price today?

One share of IRWD stock can currently be purchased for approximately $20.68.

How big of a company is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals has a market capitalization of $3.20 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

How can I contact Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]


MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  749
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: How Short Selling Works

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.